Results 61 to 70 of about 26,068 (276)

Efficacy of low-dose spironolactone on top of angiotensin receptor blockade in patients with glomerulonephritis

Kidney Research and Clinical Practice, 2018
Background: Previous studies have shown that aldosterone antagonists have a proteinuria-lowering effect in patients with proteinuria and progressive proteinuric disease not adequately controlled by the use of angiotensin receptor blockers (ARBs ...
Byung Chul Yu, Min Sung Lee, Jong Joo Moon, Soo Jeong Choi, Jin Kuk Kim, Seung Duk Hwang, Moo Yong Park   +6 more
doaj   +1 more source

Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay. [PDF]

, 2017
BackgroundGlucocorticoid receptor (GR) activity plays a role in many aspects of human physiology and may play a crucial role in chemotherapy resistance in a wide variety of solid tumors.
Block, Thaddeus S, Lynch, Frank J, Munster, Pamela N, Murphy, Tiffany I, Nguyen, Dat P   +4 more
core   +2 more sources

Why are mineralocorticoid receptor antagonists cardioprotective? [PDF]

Naunyn-Schmiedeberg's Archives of Pharmacology, 2006
Two clinical trials, the Randomized ALdosterone Evaluation Study (RALES) and the EPlerenone HEart failure and SUrvival Study (EPHESUS), have recently shown that mineralocorticoid receptor (MR) antagonists reduce mortality in patients with heart failure on top of ACE inhibition.
Chai, W (Wenxia), Danser, Jan
openaire   +3 more sources

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Evidence for Aldosterone Antagonism in Heart Failure

Cardiac Failure Review
Activation of the renin–angiotensin–aldosterone system is the ultimate pathophysiological hallmark in heart failure. Though aldosterone primarily appears to regulate electrolyte homeostasis by acting on distal nephrons in the kidneys, its effects are far-
Rishi Sethi, Pravesh Vishwakarma, Akshyaya Pradhan   +2 more
doaj   +1 more source

Socio‐economic inequalities and heart failure morbidity and mortality: A systematic review and data synthesis

ESC Heart Failure, Volume 12, Issue 2, Page 927-941, April 2025.
Abstract Socio‐economic status (SES) has been associated with incident and prevalent heart failure (HF), as well as its morbidity and mortality. However, the precise nature of the relationship between SES and HF remains unclear due to inconsistent data. This study aims to provide a comprehensive assessment and data synthesis of the relationship between
Abdul Shakoor, Willemijn A. van Maarschalkerwaart, Jeroen Schaap, Rudolf A. de Boer, Nicolas M. van Mieghem, Eric H. Boersma, Loek van Heerebeek, Jasper J. Brugts, Robert M.A. van der Boon   +8 more
wiley   +1 more source

Design, synthesis, and evaluation of naphthalidinamide analogues as nonsteroidal mineralocorticoid receptor antagonists

Journal of Chemical Research
Inappropriate overactivation of the mineralocorticoid receptor by the steroid hormones aldosterone or cortisol contributes to the development of cardiovascular diseases.
Mingguang Zhang, Yan Pang, Yurui Zhao, Sibei Chen, Cheng Guo   +4 more
doaj   +1 more source

Discontinuation of Heart Failure Pharmacotherapy in Older Adults With Frailty

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Guideline‐directed medical therapy (GDMT) improves outcomes in heart failure irrespective of frailty status. Nevertheless, the magnitude of frailty‐associated discontinuation of GDMT remains insufficiently studied.
Ryo Nakamaru, Shiori Nishimura, Hiraku Kumamaru, Kyohei Daigo, Kayo M. Walsh, Shun Kohsaka   +5 more
doaj   +1 more source

The new Era of non-Steroidal Mineralocorticoid Antagonists in Treating Heart Failure in Diabetic Kidney Disease Patients.

Albanian Journal of Trauma and Emergency Surgery, 2022
Inappropriate activation of the mineralocorticoid receptor (MR) plays a significant role in developing hypertension, the development of cardiac pathological changes, and chronic kidney disease (CKD), where death related to cardiovascular (CV) causes is ...
Eqerem Hasani, Merita Rroji, Myftar Barbullushi   +2 more
doaj   +1 more source

Return to the workforce following first hospitalization for heart failure: a Danish nationwide cohort study [PDF]

, 2016
Background: Return to work is important financially, as a marker of functional status and for self-esteem in patients developing chronic illness. We examined return to work after first heart failure (HF) hospitalization.
Fosbøl, Emil L., Gerds, Thomas A., Gislason, Gunnar H., Jhund, Pardeep S., Kragholm, Kristian, Kristensen, Søren L., Køber, Lars, Lamberts, Morten, McMurray, John J.V., Mogensen, Ulrik M., Petrie, Mark C., Rørth, Rasmus, Torp-Pedersen, Christian, Wong, Chih   +13 more
core   +2 more sources